Psoriasis News and Research

Latest Psoriasis News and Research

PhotoMedex introduces DNA Damage Control sunscreens

PhotoMedex, Inc. a leading supplier of advanced, clinical skincare and medical laser products, today introduced DNA Damage Control, the breakthrough treatment sunscreens that feature advanced photoprotection with DNA repair technology.

5 May 2011

Anacor first quarter revenues increase to $2.2 million

Anacor Pharmaceuticals reviewed today its first quarter accomplishments and reported financial results for the quarter ended March 31, 2011.

5 May 2011

Grant Thornton Leader & Innovator of the Year award for Diplomat Specialty Pharmacy president

Phil Hagerman, president and CEO of Diplomat Specialty Pharmacy in Flint, has been named Grant Thornton Leader & Innovator of the Year.

30 Apr 2011

Healthcare advertising agencies earn Med Ad News recognition

UBM Canon has announced the winners of the 22nd annual Med Ad News Manny Awards 2011. The gala event, held at the Sheraton New York Hotel and Towers, culminated with the naming of AbelsonTaylor Inc. as Agency of the Year: Category I.

30 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

Pfizer Inc. announced today top-line results from the ORAL Standard and ORAL Step Phase 3 studies of tofacitinib, an investigational, novel, oral JAK inhibitor.

29 Apr 2011

LEO Pharma introduces new Taclonex website for plaque psoriasis treatment

LEO Pharma Inc., a wholly-owned US subsidiary of LEO Pharma A/S, makers of Taclonex brand products, today announced the launch of an enhanced and expanded website at www.taclonex.com.

28 Apr 2011

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene Corporation: “The results for the quarter were outstanding and they reflect the ongoing momentum that Celgene is creating as we leverage our business model and position our Company for long-term success”.

28 Apr 2011

ProtoKinetix, Imaginative Research Associates partner to formulate topical anti-inflammation product

ProtoKinetix, is pleased to announce, that it has entered into a Joint Venture Agreement with Imaginative Research Associates, Inc. to formulate a topical anti-inflammation product for the skin care market.

27 Apr 2011

FDA grants orphan drug status to Provectus' PV-10 for liver cancer treatment

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has received orphan drug designation by the U.S. Food and Drug Administration for Rose Bengal, the active ingredient in its novel oncology drug PV-10, for the treatment of hepatocellular carcinoma, the most common form of primary liver cancer.

27 Apr 2011

Anacor's AN2728 and GSK '052 new data to be presented at upcoming meetings

Anacor Pharmaceuticals announced today that it will present data on two of its compounds at the following conferences: “Safety and efficacy of AN2728 ointment in a phase 2b dose-ranging bilateral study of mild-to-moderate plaque psoriasis”.

25 Apr 2011

Researchers reveal how immune system distinguishes between beneficial and pathogenic organisms

The human gut is filled with 100 trillion symbiotic bacteria-ten times more microbial cells than our own cells-representing close to one thousand different species. "And yet, if you were to eat a piece of chicken with just a few Salmonella, your immune system would mount a potent inflammatory response," says Sarkis K. Mazmanian, assistant professor of biology at the California Institute of Technology (Caltech).

22 Apr 2011

Psoriasis patients still need long-established treatment alternatives

For patients with severe psoriasis, a new class of intravenous and injectable biological medicines known as "biologics" has brought about a near revolution in treatment.

21 Apr 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson today announced sales of $16.2 billion for the first quarter of 2011, an increase of 3.5% as compared to the first quarter of 2010.

19 Apr 2011

Circassia closes $98 million fundraising for lead allergy programmes

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has closed a GBP60 million fundraising. The funding round was led by Imperial Innovations, and included investments from other existing shareholders, including Invesco Perpetual.

19 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.

15 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment.

7 Apr 2011

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Idera Pharmaceuticals, Inc. today announced the presentation of data from its multiple-dose Phase 1 clinical trial of IMO-3100 in healthy subjects.

5 Apr 2011

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

New data from an independent prospective study presented last week at the 19th European Congress of Psychiatry shows treatment with Risperdal Consta is associated with a lower risk of hospitalisation in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period.

5 Apr 2011

Study reveals increased incidence of major adverse cardiac events in patients with severe psoriasis

Psoriasis is a common inflammatory skin disease, and if severe, has been demonstrated to be a risk factor for cardiovascular (CV) disease. However, the degree to which psoriasis is associated with major adverse cardiac events (MACE), such as heart attack, stroke, and cardiovascular death has not been defined. Now, new research from the University of Pennsylvania School of Medicine has revealed an increased incidence of MACE in patients with severe psoriasis.

4 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer to be presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced two upcoming presentations of preclinical data from the company's VB-111 program at the American Association for Cancer Research 102nd Annual Meeting.

1 Apr 2011

Psoriasis News and Research

Latest Psoriasis News and Research

PhotoMedex introduces DNA Damage Control sunscreens

Anacor first quarter revenues increase to $2.2 million

Grant Thornton Leader & Innovator of the Year award for Diplomat Specialty Pharmacy president

Healthcare advertising agencies earn Med Ad News recognition

Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

LEO Pharma introduces new Taclonex website for plaque psoriasis treatment

Celgene non-GAAP total revenue increases 40% to $1.11 billion

ProtoKinetix, Imaginative Research Associates partner to formulate topical anti-inflammation product

FDA grants orphan drug status to Provectus' PV-10 for liver cancer treatment

Anacor's AN2728 and GSK '052 new data to be presented at upcoming meetings

Researchers reveal how immune system distinguishes between beneficial and pathogenic organisms

Psoriasis patients still need long-established treatment alternatives

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Circassia closes $98 million fundraising for lead allergy programmes

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

Study reveals increased incidence of major adverse cardiac events in patients with severe psoriasis

VBL's VB-111 preclinical data against metastatic cancer to be presented at AACR meeting

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Psoriasis News and Research

Latest Psoriasis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in